O	0	5	Pilot
O	6	11	phase
O	12	15	III
O	16	29	immunotherapy
O	30	35	study
O	36	38	in
O	39	44	early
O	44	45	-
O	45	50	stage
O	51	57	breast
O	58	64	cancer
O	65	73	patients
O	74	79	using
B-intervention	80	88	oxidized
I-intervention	89	95	mannan
I-intervention	95	96	-
I-intervention	96	100	MUC1
O	101	102	[
O	102	116	ISRCTN71711835
O	116	117	]
O	117	118	.

O	119	124	Mucin
O	125	126	1
O	127	128	(
O	128	132	MUC1
O	132	133	)
O	134	136	is
O	137	138	a
O	139	143	high
O	144	153	molecular
O	154	160	weight
O	161	173	glycoprotein
O	174	187	overexpressed
O	188	190	on
O	191	205	adenocarcinoma
O	206	211	cells
O	212	215	and
O	216	218	is
O	219	220	a
O	221	227	target
O	228	231	for
O	232	245	immunotherapy
O	246	255	protocols
O	255	256	.

O	257	259	To
O	260	264	date
O	264	265	,
O	266	274	clinical
O	275	281	trials
O	282	289	against
O	290	294	MUC1
O	295	299	have
O	300	308	included
O	309	317	advanced
O	318	324	cancer
O	325	333	patients
O	333	334	.

O	335	341	Herein
O	341	342	,
O	343	345	we
O	346	352	report
O	353	354	a
O	355	360	trial
O	361	366	using
O	367	372	early
O	373	378	stage
O	379	385	breast
O	386	392	cancer
O	393	401	patients
O	402	405	and
O	406	415	injection
O	416	418	of
O	419	427	oxidized
O	428	434	mannan
O	434	435	-
O	435	439	MUC1
O	439	440	.

O	441	443	In
O	444	445	a
O	446	456	randomized
O	456	457	,
O	458	464	double
O	464	465	-
O	465	470	blind
O	471	476	study
O	476	477	,
B-total-participants	478	480	31
B-eligibility	481	489	patients
I-eligibility	490	494	with
I-eligibility	495	500	stage
I-eligibility	501	503	II
I-eligibility	504	510	breast
I-eligibility	511	517	cancer
I-eligibility	518	521	and
I-eligibility	522	526	with
I-eligibility	527	529	no
I-eligibility	530	538	evidence
I-eligibility	539	541	of
I-eligibility	542	549	disease
O	550	558	received
O	559	571	subcutaneous
O	572	582	injections
O	583	585	of
O	586	592	either
B-control	593	600	placebo
O	601	603	or
O	604	612	oxidized
O	613	619	mannan
O	619	620	-
O	620	624	MUC1
O	624	625	,
O	626	628	to
O	629	637	immunize
O	638	645	against
O	646	650	MUC1
O	651	654	and
O	655	662	prevent
O	663	669	cancer
O	670	682	reoccurrence
O	682	683	/
O	683	693	metastases
O	693	694	.

B-total-participants	695	701	Twenty
I-total-participants	701	702	-
I-total-participants	702	707	eight
O	708	716	patients
O	717	725	received
O	726	729	the
O	730	734	full
O	735	741	course
O	742	744	of
O	745	755	injections
O	756	758	of
O	759	765	either
O	766	774	oxidized
O	775	781	mannan
O	781	782	-
O	782	786	MUC1
O	787	789	or
O	790	797	placebo
O	797	798	.

O	799	807	Survival
O	808	811	and
O	812	825	immunological
O	826	832	assays
O	833	837	were
O	838	846	assessed
O	846	847	.

O	848	853	After
O	854	858	more
O	859	863	than
O	864	865	5
O	865	866	.
O	866	867	5
O	868	873	years
O	874	877	had
O	878	885	elapsed
O	886	891	since
O	892	895	the
O	896	900	last
O	901	908	patient
O	909	914	began
O	915	924	treatment
O	925	926	(
O	926	927	8
O	927	928	.
O	928	929	5
O	930	935	years
O	936	940	from
O	941	944	the
O	945	950	start
O	951	953	of
O	954	963	treatment
O	964	966	of
O	967	970	the
O	971	976	first
O	977	984	patient
O	984	985	)
O	985	986	,
O	987	990	the
B-outcome	991	1001	recurrence
I-outcome	1002	1006	rate
O	1007	1009	in
O	1010	1018	patients
O	1019	1028	receiving
O	1029	1032	the
O	1033	1040	placebo
O	1041	1044	was
B-cv-bin-percent	1045	1047	27
I-cv-bin-percent	1047	1048	%
O	1049	1050	(
B-cv-bin-abs	1050	1051	4
O	1051	1052	/
B-control-participants	1052	1054	15
O	1054	1055	;
O	1056	1059	the
O	1060	1068	expected
O	1069	1073	rate
O	1074	1076	of
O	1077	1087	recurrence
O	1088	1090	in
O	1091	1096	stage
O	1097	1099	II
O	1100	1106	breast
O	1107	1113	cancer
O	1113	1114	)
O	1114	1115	;
O	1116	1121	those
O	1122	1131	receiving
O	1132	1145	immunotherapy
O	1146	1149	had
O	1150	1152	no
O	1153	1164	recurrences
O	1165	1166	(
B-iv-bin-abs	1166	1167	0
O	1167	1168	/
B-intervention-participants	1168	1170	16
O	1170	1171	)
O	1171	1172	,
O	1173	1176	and
O	1177	1181	this
O	1182	1189	finding
O	1190	1193	was
O	1194	1207	statistically
O	1208	1219	significant
O	1220	1221	(
O	1221	1222	P
O	1223	1224	=
O	1225	1226	0
O	1226	1227	.
O	1227	1231	0292
O	1231	1232	)
O	1232	1233	.

O	1234	1236	Of
O	1237	1240	the
O	1241	1249	patients
O	1250	1259	receiving
O	1260	1268	oxidized
O	1269	1275	mannan
O	1275	1276	-
O	1276	1280	MUC1
O	1280	1281	,
B-iv-bin-abs	1282	1286	nine
O	1287	1290	out
O	1291	1293	of
B-intervention-participants	1294	1296	13
O	1297	1300	had
B-outcome	1301	1311	measurable
I-outcome	1312	1322	antibodies
I-outcome	1323	1325	to
I-outcome	1326	1330	MUC1
O	1331	1334	and
B-iv-bin-abs	1335	1339	four
O	1340	1343	out
O	1344	1346	of
B-intervention-participants	1347	1349	10
O	1350	1353	had
B-outcome	1354	1358	MUC1
I-outcome	1358	1359	-
I-outcome	1359	1367	specific
I-outcome	1368	1369	T
I-outcome	1370	1374	cell
I-outcome	1375	1384	responses
O	1384	1385	;
B-cv-bin-abs	1386	1390	none
O	1391	1393	of
O	1394	1397	the
O	1398	1405	placebo
O	1405	1406	-
O	1406	1413	treated
O	1414	1422	patients
O	1423	1432	exhibited
O	1433	1435	an
O	1436	1442	immune
O	1443	1451	response
O	1452	1454	to
O	1455	1459	MUC1
O	1459	1460	.

O	1461	1464	The
O	1465	1472	results
O	1473	1480	suggest
O	1481	1485	that
O	1485	1486	,
O	1487	1489	in
O	1490	1495	early
O	1496	1502	breast
O	1503	1509	cancer
O	1509	1510	,
O	1511	1515	MUC1
O	1516	1529	immunotherapy
O	1530	1532	is
O	1533	1543	beneficial
O	1543	1544	,
O	1545	1548	and
O	1549	1553	that
O	1554	1555	a
O	1556	1562	larger
O	1563	1568	phase
O	1569	1572	III
O	1573	1578	study
O	1579	1585	should
O	1586	1588	be
O	1589	1599	undertaken
O	1599	1600	.
